Core Insights - Cibus, Inc. will report its second quarter 2025 financial results on August 14, 2025, with a conference call scheduled for 4:30 p.m. ET to discuss these results and other updates [1][2]. Company Overview - Cibus is a leading agricultural technology company focused on developing and licensing plant traits to seed companies, utilizing proprietary high-throughput gene editing technology [4]. - The company addresses critical productivity and sustainability challenges for farmers, particularly diseases and pests, which the United Nations estimates cost the global economy approximately $300 billion annually [4]. - Cibus is not a seed company but a technology company that licenses its innovations to seed companies in exchange for royalties on seed sales [4].

Core Insights - Cibus, Inc. has successfully closed a public offering of 15,714,285 shares of Class A Common Stock at a price of $1.75 per share, raising gross proceeds of $27.5 million [1][2] Company Overview - Cibus is a leading agricultural biotechnology company focused on developing plant traits through proprietary gene editing technologies, addressing productivity and sustainability challenges for farmers [6] - The company is not a seed company but a technology company that licenses developed crop traits to seed companies in exchange for royalties on seed sales [6] Use of Proceeds - The net proceeds from the offering will be utilized for the development of weed management productivity traits in rice, as well as for working capital and general corporate purposes [2] Offering Details - The offering was conducted under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission, with A.G.P./Alliance Global Partners acting as the sole placement agent [3][4]

Core Viewpoint - Cibus, Inc. has announced a public offering of 15,714,285 shares of its Class A Common Stock at a price of $1.75 per share, aiming to raise approximately $27.5 million for further development and working capital [1][2]. Company Overview - Cibus is a leading agricultural biotechnology company specializing in gene editing technologies to develop plant traits in seeds, focusing on productivity traits for major crops [6]. - The company addresses significant agricultural challenges, including diseases and pests, which the United Nations estimates cost the global economy around $300 billion annually [6]. - Cibus operates as a technology company rather than a seed company, licensing its developed traits to seed companies for royalties on seed sales [6]. Offering Details - The offering consists solely of shares sold by Cibus, with gross proceeds expected to be approximately $27.5 million before expenses [2]. - The offering is anticipated to close on or about June 6, 2025, pending customary closing conditions [2]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for this offering [3]. Use of Proceeds - The net proceeds from the offering will be utilized to fund the development of weed management productivity traits in rice and for general corporate purposes [2]. Regulatory Information - The offering is made under an effective shelf registration statement filed with the U.S. Securities and Exchange Commission, with a prospectus supplement to be filed [4].

Core Viewpoint - Cibus, Inc. plans to offer shares of its Class A common stock in a public offering, with the Chairman expressing interest in purchasing up to $10 million of shares [1][2]. Group 1: Offering Details - The offering will be conducted by Cibus and is subject to market conditions, with no assurance on the completion or terms of the offering [1]. - A.G.P./Alliance Global Partners is acting as the sole placement agent for the offering [2]. - The securities will be offered under an effective shelf registration statement filed with the SEC [3]. Group 2: Use of Proceeds - The net proceeds from the offering are intended to fund the development of weed management productivity traits in rice and for general corporate purposes [2]. Group 3: Company Overview - Cibus is a leader in gene-edited productivity traits aimed at addressing significant agricultural challenges, with an estimated global economic cost of $300 billion annually due to diseases and pests [5]. - The company focuses on developing crop traits using proprietary gene editing technology, which is faster and more cost-effective than traditional breeding methods [5].